Determine, Inc. (DTRM) Forms $2.03 Double Bottom; 2 Analysts Are Bullish Sunesis Pharmaceuticals, Inc. (SNSS) Last Week

Determine, Inc. (DTRM) formed double bottom with $1.95 target or 4.00% below today’s $2.03 share price. Determine, Inc. (DTRM) has $30.06M valuation. The stock increased 6.29% or $0.1201 during the last trading session, reaching $2.0301. About 101,903 shares traded or 132.37% up from the average. Determine, Inc. (NASDAQ:DTRM) has risen 186.29% since January 7, 2017 and is uptrending. It has outperformed by 169.59% the S&P500.

Among 5 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Sunesis Pharmaceuticals had 11 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) earned “Buy” rating by Oppenheimer on Monday, November 20. On Tuesday, December 5 the stock rating was downgraded by Wells Fargo to “Market Perform”. On Friday, July 24 the stock rating was downgraded by Cantor Fitzgerald to “Hold”. Cantor Fitzgerald maintained it with “Hold” rating and $300 target in Tuesday, July 18 report. The firm has “Sell” rating by TH Capital given on Friday, July 24. The company was upgraded on Monday, December 11 by Wells Fargo. The firm has “Buy” rating given on Thursday, December 14 by Oppenheimer. The firm earned “Hold” rating on Thursday, July 27 by Cantor Fitzgerald. As per Friday, July 24, the company rating was downgraded by Cowen & Co. The stock has “Outperform” rating by Wells Fargo on Friday, July 29. See Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) latest ratings:

14/12/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate
11/12/2017 Broker: Wells Fargo Rating: Buy Upgrade
05/12/2017 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Downgrade
20/11/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate
02/11/2017 Broker: Cowen & Co Rating: Hold
27/07/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $3.0000 Maintain
18/07/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $3.0000 Maintain

The stock increased 5.18% or $0.19 during the last trading session, reaching $3.86. About 72,130 shares traded. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has risen 8.33% since January 7, 2017 and is uptrending. It has underperformed by 8.37% the S&P500.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company has market cap of $132.20 million. The firm is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia . It currently has negative earnings. It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.

Analysts await Determine, Inc. (NASDAQ:DTRM) to report earnings on February, 8. They expect $-0.17 EPS, down 30.77% or $0.04 from last year’s $-0.13 per share. After $-0.14 actual EPS reported by Determine, Inc. for the previous quarter, Wall Street now forecasts 21.43% negative EPS growth.